EVMN
HEALTHCAREEvommune Inc
Live · NYSE · May 9, Close
What's Moving EVMN Today?
No stock-specific AI insight has been generated for EVMN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$23.83
Fundamentals
Trading
EVMN News
20 articles- Evommune Reports First Quarter 2026 Financial Results and Provides Business HighlightsYahoo Finance·May 7, 2026
- Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC SaysYahoo Finance·Apr 10, 2026
- Biotech’s IPO comeback; Trump’s tariff loophole for pharmaPharmavoice·Apr 10, 2026
- Evommune bucked biotech IPO drought and is focused on the long gamePharmavoice·Apr 7, 2026
- Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in MigraineYahoo Finance·Apr 6, 2026
- Apogee strengthens case for longer-lasting eczema drugBiopharmadive·Mar 23, 2026
- Evommune Stock Sees RS Rating Rise To 91Yahoo Finance·Mar 18, 2026
- Block upgraded, Starbucks downgraded: Wall Street's top analyst callsYahoo Finance·Mar 18, 2026
- 1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next DecadeMotley Fool·Mar 10, 2026
- Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business HighlightsYahoo Finance·Mar 5, 2026
- Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO SuccessYahoo Finance·Feb 25, 2026
- Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m PlacementYahoo Finance·Feb 14, 2026
- Evommune Announces $125 Million Private PlacementYahoo Finance·Feb 13, 2026
- Evommune’s stock rallies 70% on Phase IIa eczema dataClinicaltrialsarena·Feb 11, 2026
- Evommune rockets on eczema data; AstraZeneca advances GLP-1 pillBiopharmadive·Feb 11, 2026
- Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.Yahoo Finance·Feb 10, 2026
- Sector Update: Health Care Stocks Mixed Late AfternoonYahoo Finance·Feb 10, 2026
- Top Midday GainersYahoo Finance·Feb 10, 2026
- Sector Update: Health Care Stocks Mixed Tuesday AfternoonYahoo Finance·Feb 10, 2026
- Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic DermatitisYahoo Finance·Feb 10, 2026
All 20 articles loaded
Price Data
52-Week Range
$23.83
Fundamentals
Trading
About Evommune Inc
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for the treatment of immunological disorders. With a robust pipeline designed to tackle significant unmet medical needs, Evommune leverages advanced research and technology to enhance immune response and patient outcomes. The company's dedication to scientific rigor and strategic partnerships supports its ambition to become a leader in the rapidly evolving field of immunotherapy. As Evommune progresses through clinical trials, it aims to deliver transformative solutions that could redefine care standards in immunology and provide renewed hope for patients.